Dear Authors,
If you believe that your paper was mistakenly rejected by other leading journals and you do not agree with final decision, the editors of Reports of Practical Oncology and Radiotherapy offer new fast track review. You may submit your manuscript to Reports of Practical Oncology and Radiotherapy together with all prior peer-reviews obtained from the other journal and your rebuttal letter. We guarantee review based decision within 72 hours from the time we will receive your manuscript.

Fast track submission process: Please submit the manuscript with all reviews and rebuttal letter by email to Dr. Michal Masternak ( for fast review processing. To assure immediate attention the email title must to include: RPOR-fast track- Last Name First Name (of corresponding author).

Volume 9, Number S2, 2004

Brachytherapy HDR in interoperative breast cancer treatment

J. Hammer, M. Jurczyk, S. Sajdak, P. Jankowski, M. Pisarska


Purpose: To present data from Linz, Austria, on survival and local control of a prospective treatment method and to demonstrate the safe use of combined external beam and interstitial Iridium-192 HDR irradiation. This method has been transferred to Gynecological Clinic in Poznan, Poland, where the first implantation was performed in January 2004.
Patients & Methods: a) Linz: Since 1984 HDR Ir-192 brachytherapy has been used to deliver an interstitial boost to the primary site in conservative breast cancer treatment. Until December 1995, 650 patients have been treated (T1:434, T2: 216, N0: 467, N1: 183). Treatment method (after tumourectomy or qadrantectomy) included external beam irradiation of 45 to 50 Gy to the breast followed by an interstitial 10 Gy boost. Mean follow up of survivors: 105 months (range 36 to 189).
b) Poznan: Ina 54 years old patient with breast cancer carcinoma ductale infiltrans G.2 pT2 tumourectomy was performed. In the same surgical session hollow needles where implanted into the tumour bed. Using an Iridium-192 source interstitial radiotherapy was delivered with a dose of 10 Gy as boost to the primary site.
Results: 5-years actuarial data for T1-2 tumours: Overall survival: 89.2%, local control: 96.9%, disease free survival: 86.4%, and disease specific survival: 92.8%. There were no severe complications, the cosmetic results are satisfactory (91% good to excellent after 5 years).
Conclusion: The use of a HDR source in boosting the primary tumour site with a dose of 10 Gy in 1 fraction after external beam radiotherapy is a safe procedure; the impact on cosmetic results is minimal. Our 5-year local relapse rate of 3.1% and survival
data are satisfactory and better compared to most of the results reported in literature. Therefore we will continue with the described prospective approach in Linz. The first implantation in Poznan was the kick off for further brachytherapy treatments
in breast cancer patients. High dose rate implantantions in the treatment of breast cancer will continue at the Gynecological Clinic in Poznan, either as a boost or as the sole treatment of mammary glant carcinoma.

Signature: Rep Pract Oncol Radiother, 2004; 9(S2) : 275-275


« back


Indexed in: EMBASE®, the Excerpta Medica database, the Elsevier BIOBASE (Current Awareness in Biological Sciences) and in the Index Copernicus.